AlphaCentric Advisors’s United Therapeutics UTHR Stock Holding History

AlphaCentric Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,250	Closed	-$2.24M	–	280
2024 Q3	$2.24M	Sell	6,250 -8,250	-57%	-$2.79M	1.67%	14
2024 Q2	$4.62M	Sell	14,500 -1,500	-9%	-$397K	3.4%	1
2024 Q1	$3.68M	Buy	+16,000	New	+$3.61M	2.22%	4
2023 Q4	–	Sell	-9,000	Closed	-$2.03M	–	283
2023 Q3	$2.03M	Hold	9,000	–	–	1.15%	26
2023 Q2	$1.99M	Buy	9,000 +5,500	+157%	+$1.22M	1.1%	26
2023 Q1	$784K	Buy	3,500 +1,250	+56%	+$308K	0.54%	66
2022 Q4	$626K	Hold	2,250	–	–	0.62%	60
2022 Q3	$471K	Buy	+2,250	New	+$503K	0.48%	59
2021 Q4	$238K	Buy	1,100 +550	+100%	+$108K	0.07%	96
2021 Q3	$102K	Hold	550	–	–	0.03%	163
2021 Q2	$99K	Hold	550	–	–	0.03%	172
2021 Q1	$92K	Sell	550 -200	-27%	-$33.3K	0.03%	162
2020 Q4	$114K	Sell	750 -76	-9%	-$9.97K	0.05%	109
2020 Q3	$83K	Buy	+826	New	+$90.6K	0.04%	71

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AlphaCentric Advisors's UTHR Position: Q4 2024 in Review

AlphaCentric Advisors sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 6,250 shares — an estimated $2.24M sold.

AlphaCentric Advisors first reported a position in UTHR in Q3 2020 and held it in 14 quarters. The position peaked at $4.62M in Q2 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

AlphaCentric Advisors reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 6,250 United Therapeutics shares in Q4 2024, an estimated $2.24M.
AlphaCentric Advisors first reported a position in United Therapeutics in Q3 2020 and held it in 14 quarters.
AlphaCentric Advisors's United Therapeutics position peaked at $4.62M in Q2 2024.
673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.